<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04648813</url>
  </required_header>
  <id_info>
    <org_study_id>BIO REB 1959</org_study_id>
    <nct_id>NCT04648813</nct_id>
  </id_info>
  <brief_title>Tiotropium Efficacy Against Allergen Induced Early Asthmatic Responses</brief_title>
  <official_title>Tiotropium Efficacy Against Allergen Induced Early Asthmatic Responses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Saskatchewan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Saskatchewan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will compare the effect of inhaled tiotropium versus placebo on allergen induced&#xD;
      early asthmatic responses in individuals with atopic asthma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, double-blind, randomized, placebo-controlled, crossover study. The&#xD;
      study will consist of two one week treatment periods, one with tiotropium (two&#xD;
      inhalations/5mcg/day) and one with placebo (2inhalations/day). A minimum two week washout&#xD;
      period between treatments is required. Four visits over the course of approximately 4 weeks&#xD;
      will be required to complete the study. Procedures at each visit are as follows:&#xD;
&#xD;
      Visit 1:&#xD;
&#xD;
      Participants will undergo consent procedures and if consent is provided measurements of FeNO,&#xD;
      spirometry, airway responsiveness to methacholine, skin prick testing, skin titration&#xD;
      endpoint testing and sputum induction will be performed. If participants meet eligibility&#xD;
      criteria following these assessments, treatment 1 will be dispensed and the first dose&#xD;
      administered. The participant will then self administer the treatment for the next six days&#xD;
      (i.e. a total of 7 days of treatment) before returning for Visit 2.&#xD;
&#xD;
      Visit 2:&#xD;
&#xD;
      A final dose of treatment 1 will be administered. At 30 minutes post dose, FeNO testing,&#xD;
      spirometry measurements and allergen inhalation challenge will be performed. Five hours after&#xD;
      the allergen challenge, FeNO will again be measured and sputum induction will be performed.&#xD;
&#xD;
      Visits 3 and 4:&#xD;
&#xD;
      Visits 3 and 4 will be identical to Visit 1 and 2 except that no skin prick testing or skin&#xD;
      titration endpoint testing will be required. At Visit 3 participants will be crossed over to&#xD;
      treatment 2 and the first dose will be administered. Participants will self administer&#xD;
      treatment 2 for the next six days before returning for Visit 4.&#xD;
&#xD;
      The primary endpoint will be the EAR PD20, the amount of allergen required to induce an early&#xD;
      asthmatic response (i.e. a fall in FEV1 post allergen inhalation of 20% or more) tiotropium&#xD;
      versus placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 13, 2020</start_date>
  <completion_date type="Actual">April 20, 2021</completion_date>
  <primary_completion_date type="Actual">April 20, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EAR PD20</measure>
    <time_frame>30 minutes post last dose of treatment</time_frame>
    <description>amount of inhaled allergen required to induce a 20% fall in FEV1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Airway inflammation</measure>
    <time_frame>pre-treatment, 30 minutes post final dose and 5 hours post allergen inhalation challenge</time_frame>
    <description>level of FeNO (fractional exhaled nitric oxide) in parts per billion (ppb)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Airway inflammation</measure>
    <time_frame>pre treatment and 5 hours post allergen inhalation challenge</time_frame>
    <description>change in number of sputum differential cell counts, specifically eosinophils</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Allergic Asthma</condition>
  <arm_group>
    <arm_group_label>tiotropium bromide monohydrate (Spiriva Respimat)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium bromide monohydrate (Spiriva Respimat)</intervention_name>
    <description>administered daily, 2 inhalations/5mcg per dose for a total of 8 doses</description>
    <arm_group_label>tiotropium bromide monohydrate (Spiriva Respimat)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>matching placebo</intervention_name>
    <description>administered daily, 2 inhalations per dose for a total of 8 doses</description>
    <arm_group_label>matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
          -  diagnosis of mild asthma with a minimum 3 months history at the time of enrolment into&#xD;
             the trial&#xD;
&#xD;
          -  pre-bronchodilator FEV1 80% or greater than the predicted value&#xD;
&#xD;
          -  positive response to inhaled methacholine (i.e. MCh PD20 ≤ 400mcg)&#xD;
&#xD;
          -  evidence of atopy (i.e. positive skin prick test to an allergen that is appropriate&#xD;
             for use in allergen inhalation challenge)&#xD;
&#xD;
          -  no respiratory infection within 4 weeks of Visit 1&#xD;
&#xD;
          -  no allergen exposure within 4 weeks of Visit 1&#xD;
&#xD;
          -  current non-smoker (ex-nicotine smoker with &lt; 10 pack years evaluated case by case)&#xD;
&#xD;
          -  use of β2 agonist rescue medications less than daily and no more than 4 times per week&#xD;
&#xD;
          -  general good health with no other medical condition, medication use or lifestyle&#xD;
             activities that would potentially alter the outcome of the allergen challenge&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  currently pregnant or breast-feeding&#xD;
&#xD;
          -  current daily use of other inhaled recreational products (e.g. cannabis, e-cigarettes&#xD;
             or other vaping products; occasional use requires 24 hour withhold)&#xD;
&#xD;
          -  diagnosis or evidence of narrow angle glaucoma&#xD;
&#xD;
          -  diagnosis or evidence of urinary retention&#xD;
&#xD;
          -  known hypersensitivity to tiotropium, atropine or its derivatives (e.g. ipratropium)&#xD;
             or components of tiotropium formulation (e.g. benzalkonium chloride)&#xD;
&#xD;
          -  history of anaphylaxis or angioedema&#xD;
&#xD;
          -  current use of :&#xD;
&#xD;
          -  inhaled corticosteroid including combination therapies&#xD;
&#xD;
          -  inhaled muscarinic antagonists - except study treatment (e.g. ipratropium bromide)&#xD;
&#xD;
          -  long-acting beta2-agonists (LABA; e.g. formoterol)&#xD;
&#xD;
          -  leukotriene receptor antagonists (e.g. montelukast)&#xD;
&#xD;
          -  biologics (e.g. benralizumab)&#xD;
&#xD;
          -  allergen immunotherapy&#xD;
&#xD;
          -  mast cell stabilizers (e.g. nedocromil sodium)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asthma Research Lab University of Saskatchewan Room 346 Ellis Hall</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Saskatchewan</investigator_affiliation>
    <investigator_full_name>Beth Davis</investigator_full_name>
    <investigator_title>Research Scientist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

